Submit Manuscript

International Journal of Pharmacology

Year: 2018 | Volume: 14 | Issue: 1 | Page No.: 1-8
Research Article

Comparing the Efficacy, Safety and Cost of the Anticoagulants: Rivaroxaban and Nadroparin in Hip Replacement Surgery

Shilin Jiang
Department of Orthopedics, Shanghai Jiangong Hospital, 200083 Shanghai, China
LiveDNA: 86.16473
Liang Du
Department of Orthopedics, Shanghai Jiangong Hospital, 200083 Shanghai, China
Cheng Ni
Department of Orthopedics, Shanghai Jiangong Hospital, 200083 Shanghai, China
Background and Objective: Many anticoagulants have significant drawbacks: Aspirin has limited efficacy, warfarin is highly effective but the dosage must be monitored and adjusted carefully and dabigatran is effective but may be lethal. The current study compares the efficacy of rivaroxaban, low-dose nadroparin calcium and high-dose nadroparin calcium for thromboprophylaxis in patients after total hip replacement (THR) surgery. Materials and Methods: A total of 831 THR surgery patients were enrolled in this randomized, three-arm study (n = 277 for each of three groups). Group I patients received rivaroxaban (10 mg), group II patients received low-dose nadroparin calcium (3,000 anti-Xa IU kg–1 b.wt.) and group III patients received high-dose nadroparin calcium (6,500 anti-Xa IU kg–1 b.wt.). Follow-up visits with patients were conducted 40 days after the intervention. Outcomes were measured using D-dimer test assays, angiography and digital color Doppler scanner ultrasound. Additionally, the cost of treatment was calculated for each patient. A two-tailed paired t-test and Dunnett’s multiple comparison tests were used to compare measured outcomes and the cost of therapy between groups I and II and between groups I and III at a 95% confidence level. Results: Efficacy outcomes for group I were superior to those of group II (p<0.05 for all outcomes) and comparable to those of group III (p>0.05 for all outcomes). The 10 mg rivaroxaban treatment had a major bleeding event in the gastrointestinal tract and liver. Adverse effects of nadroparin included hyperkalemia, skin rash and leg weakness. The cost of therapy was highest for group III and lowest for group I. Conclusion: Rivaroxaban and nadroparin are both effective as thromboprophylactic drugs in patients following THR surgery and have few adverse effects. Physicians may successfully use any of these therapies according to the patient’s condition.
PDF Fulltext XML References Citation

Leave a Comment

Your email address will not be published. Required fields are marked *

Article Trend

Total views 3359

References

  1. Al-Horani, R.A. and U.R. Desai, 2016. Factor XIa inhibitors: A review of the patent literature. Expert Opin. Ther. Patents, 26: 323-345.
    CrossRefDirect Link
  2. Malhotra, R., S. Babhulkar, K.B. Sanjib, A. Clemens and A. Dadi et al., 2017. Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study. Asian J. Surg., 40: 145-151.
    CrossRefDirect Link
  3. Garcia-Olivares, P., J.E. Guerrero, E. Keough, P. Galdos and D. Carriedo et al., 2016. Clinical factors associated with inappropriate prophylaxis of venous thromboembolic disease in critically ill patients. A single day cross-sectional study. Thrombosis Res., 143: 111-117.
    CrossRefDirect Link
  4. Patel, M.R., K.W. Mahaffey, J. Garg, G. Pan and D.E. Singer et al., 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Eng. J. Med., 365: 883-891.
    CrossRefPubMedDirect Link
  5. Mommsen, P., M. Doering, C. Egidy, T. Gehrke, C. Krettek and D. Kendoff, 2014. Effects of thromboembolism prophylaxis with dabigatran on perioperative blood loss and wound secretion in primary hip arthroplasty. Technol. Health Care, 22: 901-908.
    CrossRefDirect Link
  6. Stewart, D.W. and J.E. Freshour, 2013. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: A comparison of the AAOS and ACCP guidelines with review of the evidence. Ann. Pharm., 47: 63-74.
    Direct Link
  7. Ventura, F., A. Bonsignore, F. De Stefano, E. Pizzorno and C. Palmiere, 2014. Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty. Forensic Sci. Med. Pathol., 10: 619-622.
    CrossRefDirect Link
  8. Weitz, J.I., A.W. Lensing, M.H. Prins, R. Bauersachs and J. Beyer-Westendorf et al., 2017. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N. Engl. J. Med., 376: 1211-1222.
    CrossRefDirect Link
  9. Karlberg, J.P.E. and M.A. Speers, 2010. Reviewing Clinical Trials: A Guide for the Ethics Committee. The University of Hong Kong, Clinical Trials Centre, Hong Kong, ISBN: 9789881904119, Pages: 153.
  10. Charan, J. and T. Biswas, 2013. How to calculate sample size for different study designs in medical research? Indian J. Psychol. Med., 35: 121-126.
    CrossRefDirect Link
  11. Min, S.K., Y.H. Kim, J.H. Joh, J.M. Kang and U.J. Park et al., 2016. Diagnosis and treatment of lower extremity deep vein thrombosis: Korean practice guidelines. Vascular Specialist Int., 32: 77-104.
    CrossRefDirect Link
  12. Eriksson, B.I., L.C. Borris, R.J. Friedman, S. Haas and M.V. Huisman et al., 2008. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med., 358: 2765-2775.
    CrossRefDirect Link
  13. Guerin, S., C. Collins, H. Kapoor, I. McClean and D. Collins, 2007. Blood transfusion requirement prediction in patients undergoing primary total hip and knee arthroplasty. Transfusion Med., 17: 37-43.
    CrossRefDirect Link
  14. Viera, A.J. and N. Wouk, 2015. Potassium disorders: Hypokalemia and hyperkalemia. Am. Family Phys., 92: 487-495.
    Direct Link
  15. Blanchard, C., F. Pattou, L. Brunaud, A. Hamy and M. Dahan et al., 2017. Randomized clinical trial of ultrasonic scissors versus conventional haemostasis to compare complications and economics after total thyroidectomy (FOThyr). BJS Open, 1: 2-10.
    CrossRefDirect Link
  16. Shafiq, N., S. Malhotra, P. Pandhi, N. Sharma, A. Bhalla and A. Grover, 2006. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins-enoxaparin, nadroparin and dalteparin. Pharmacology, 78: 136-143.
    CrossRefDirect Link
  17. Leung, V., E. Zhang and D.S. Pang, 2016. Real-time application of the rat grimace scale as a welfare refinement in laboratory rats. Scient. Rep., Vol. 6.
    CrossRefDirect Link
  18. Gao, Z., F. Cui, X. Cao, D. Wang, X. Li and T. Li, 2017. Local infiltration of the surgical wounds with levobupivacaine, dexibuprofen and norepinephrine to reduce postoperative pain: A randomized, vehicle-controlled and preclinical study. Biomed. Pharmacother., 92: 459-467.
    CrossRefPubMed
  19. Heckmann, M., H. Thermann and F. Heckmann, 2015. Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty. Hamostaseologie, 35: 358-363.
    CrossRefPubMedDirect Link
  20. Beyer-Westendorf, J., J. Luetzner, L. Donath, L. Tittl and H. Knoth et al., 2013. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery. Thrombosis Haemostasis, 109: 154-163.
    CrossRefDirect Link
  21. Nayak, B.K., 2010. Understanding the relevance of sample size calculation. Indian J. Ophthalmol., 58: 469-470.
    CrossRefDirect Link
  22. Brown, D.G., E.C. Wilkerson and W.E. Love, 2015. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J. Am. Acad. Dermatol., 72: 524-534.
    CrossRefDirect Link
  23. Mo, Y. and F.K. Yam, 2015. Recent advances in the development of specific antidotes for targetā€specific oral anticoagulants. Pharm.: J. Hum. Pharmacol. Drug Ther., 35: 198-207.
    CrossRefDirect Link
  24. Gheno, G., L. Cinetto, C. Savarino, S. Vellar, M. Carraro and M. Randon, 2003. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur. J. Clin. Pharmacol., 59: 373-377.
    CrossRefDirect Link
  25. PrFRAXIPARINEĀ®, 2015. Product Monograph. Aspen Pharma Trading Ltd., Dublin.
  26. Zindel, S., S. Stock, D. Muller and B. Stollenwerk, 2012. A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv. Res., Vol. 12.
    CrossRef

Keywords